AGWCA
VTGN icon

Annis Gardner Whiting Capital Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-600
Closed -$343 – 1234
2026
Q1 		$343 Buy
+600
New +$365 ﹤0.01% 1232

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's VTGN Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 600 shares — an estimated $343 sold.

Annis Gardner Whiting Capital Advisors first reported a position in VTGN in Q1 2026 and held it in 1 quarter. The position peaked at $343 in Q1 2026. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 600 VistaGen Therapeutics shares in Q2 2026, an estimated $343.
  • Annis Gardner Whiting Capital Advisors first reported a position in VistaGen Therapeutics in Q1 2026 and held it in 1 quarter.
  • Annis Gardner Whiting Capital Advisors's VistaGen Therapeutics position peaked at $343 in Q1 2026.
  • 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.